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Dr Tara Karamlou (San Francisco, Calif). Thank you, Dr
Khan. Dr Khan and colleagues are to be commended for tackling
the problem of determining the ‘‘ideal’’ AoV intervention for AoV
disease in pediatric patients. The study was well conceived and ex-
ecuted, represents one of the largest series of infants undergoing
intervention, and Dr Khan provided the manuscript to me well in
advance of the meeting. The 98% survival is commendable and
the 85% follow-up of the cohort, which included outreach to pa-
tients not followed up at their institution, is also excellent. The
study is a retrospective review of 285 AoV repairs and replace-
ments in 241 patients over a 16-year period. The authors report
that for valve repair, infants and those with truncus arteriosus
had higher risk for the primary composite end point of death and
reoperation. Similarly, risk factors for the composite end point
for valve replacement cases included infants, those with concom-
itant CHD, and those having homograft valves.520 The Journal of Thoracic and Cardiovascular SurgThe good points regarding the study notwithstanding, the results
elucidated are not novel inasmuch as several prior publications
have shown that patients of younger age, those receiving homo-
graft valves, and those with concomitant CHD including truncus
arteriosus to have worse outcomes than other pediatric patients un-
dergoing AoV intervention.
With this in mind, I have several questions for the authors.
The authors stated in their conclusions, and some of these are
conclusions from the manuscript and not necessarily from the pre-
sentation, that patients having homograft valve replacements have
lower freedom from their composite end point of reoperation and
death. Patients having homografts, however, were significantly
younger and had significantly smaller valves implanted, often 15
mm versus 22 mm for the other valve types, compared with other
replacement patients. Furthermore, the authors stated that they had
adopted a policy to ‘‘stage’’ smaller children with an intervening
homograft valve before performing an index Ross operation. In
other words, replacing the homograft was really a fait accompli.
Finally, since era was not mentioned as a covariate, and consider-
ing the fact that the study circumscribed a broad historical period,
was the policy of staging patients adopted on the basis of a prior
analysis of patients undergoing the Ross operation from your
own institution?
In other words, my question is, based on these confounders, do
the authors believe that their study may be unfairly biased against
homograft valves?
Dr Khan. Thank you, Dr Karamlou, for your thoughtful com-
ments. We agree with your observation that much of what we pres-
ent in this paper is not novel; however, many of those data you refer
to represent aggregatemulti-institutional series andwe believe that
it is important for individual institutions to carefully monitor their
own experience as this is the end point between the patient and the
heart team.
Regarding the questions, we purposely elected to study a time
frame representative of a consistent management strategy and
team. Although multiple surgeons were involved, the approach
to smaller patients, particularly those in whom there is a very
large size discrepancy between the pulmonary valve and native
or reconstructed aortic root, has remained constant. Our thinking
has been that using a small homograft as a primary reconstructive
method with the expectation, as you correctly note, of an early
reoperation on the root allows a more durable application of
the Ross procedure. This has been borne out in our experience
with a low risk of subsequent Ross procedure after primary ho-
mograft root replacement. That being said, given our current
data analysis, we are likely to adopt at our institution a somewhat
more liberal application of the Ross procedure in smaller
children.
Dr Karamlou. I was confused by the statement made in the
manuscript that complex valve repairs fared no worse than simple
valve repairs. First, the complex repair group included all of the
truncal valve interventions, which were identified as a risk factor
for reoperation and death, and the Kaplan-Meier plot showed
a 5-year freedom from your composite end point of 84% for simple
repairs compared with a 5-year freedom of 61% for complex re-
pairs. Although the P value reported is .07, the curves are impres-
sively different. Considering the difference in follow-up favoring
the simple group, do the authors really believe that there is noery c September 2013
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Dclinically important difference among these groups? In other
words, is this really a type 2 error?
Dr Khan.We agree that this might be actually clinically signif-
icant difference, but statistically it was not significant. That is what
we reported, and we made a slight change in the final manuscript.
Dr Karamlou. Can the authors elaborate on their institutional
approach to patients with truncal valve dysfunction? Considering
the considerably worse outcomes in this group, at what age and
at what level of dysfunction do they recommend intervening on
the valve?
Dr Khan. Regarding our approach to truncal valves, we have
chosen to be aggressive with repair even at that time of the primary
operation. As you know, acute significant truncal insufficiency is
an important risk factor for patients undergoing truncus repair.
As such, we have liberally approached various truncal valve repair
methods including rudimentary sinus resection, leaflet suspension
and extension, and bicuspidization. For irreparable truncal valves,
we agree that mechanical valve replacement is a useful option but
have elected to defer this option in most cases until a suitably large
valve can be placed to limit the potential of somatic outgrowth. We
also favor minimizing the obligate challenges associated with
managing warfarin in children.
Dr Ross Ungerleider (Winston-Salem, NC). Very nice. It is
a wonderful series. I am sitting here trying towrapmy brain around
it and so I hope my questions are not na€ıve.
First of all, you started out your presentation with this case his-
tory of a woman with multiple reinterventions but not death. I am
puzzled why you would combine freedom from death or reinter-
vention in your graphs because they are very different outcomes.
As you go about revising this manuscript, you might find it useful
to separate those two things out because death is such a different
outcome. It may be the eventual outcome of multiple reinterven-
tions. Can you comment about why you chose to put those two to-
gether? I think they might obscure some of the conclusions that
you are trying to make.
DrKhan. Thank you for your question. The primary reason that
we chose to include death and reintervention together is that we
were trying to show the worst case scenario from a valve replace-
ment. The most difficult question to answer is when a parent asks,
‘‘How long will the valve survive?’’ We wanted to present the
whole picture to parents.
Dr Ungerleider. Another question is that your incidence
of right ventricle–pulmonary artery conduit replacement in theThe Journal of Thoracic and Capatients with autografts was high at 26%. Could you comment
on that? Do you think that some of that was related to patients out-
growing their conduit or did you have a conduit deterioration rate
that was about a quarter of the patients? I am curious what conduit
you are using in those cases.
Dr Khan. I would ask Dr Fraser to comment on the type of con-
duit that we use.
Dr Fraser.Dr Ungerleider, thanks for your comments. We used
almost exclusively homografts, but I think we are fairly aggressive
about reintervening on the right ventricle–pulmonary artery con-
duit. As you know, the Contegra conduit (Medtronics) is not
even approved for use in this indication, sowe inserted only 2 Con-
tegra homografts in this series, but we have a relatively aggressive
institutional stance to conduit replacement. In our experience, ho-
mografts in the current era are not particularly predictable.
Dr Ungerleider. I think there are a lot of conduits out there that
are not being replaced but are dysfunctional. In the past year, we
have been making polytetrafluoroethylene (W.L. Gore & Associ-
ates, Inc, Flagstaff, Ariz) valves. We have altered the technique
that Jim Quintessenza has described and are making trileaflet
valves. Jim has been making bileaflet polytetrafluoroethylene
valves. We are placing these valves in a tube, similar to our mod-
ified Ross procedure. We think these may be better than allografts.
I do not know, but it just was an interesting number. It caught my
attention.
Finally, why did you include the truncus patients in this? I know
they are getting AoV replacements. However, because some op-
tions are not available to them, they may also tend to obscure
and contaminate the data unless they are looked at as a separate
group. They cannot get autografts, for example. I am just curious
about the thinking of including them.
Dr Fraser. As Dr Khan noted, our goal was to present the
worst case scenario for aortic root interventions in our hospital.
Notwithstanding the fact that there are multiple other previous
series published, we thought that having a snapshot of what we
have been doing in our hospital and particularly in the context
of counseling families at the time of this difficult decision is im-
portant. I find the AoV consults with families one of the most
difficult and lengthy consults I have with patients before surgery.
Trying to provide them the profile of all-comers and what our
experience has been seemed important. Admittedly, the truncus
patients are the worst actors in terms of truncal/AoV durability
and risk profile.rdiovascular Surgery c Volume 146, Number 3 521
